China-based chemical companies, often through special private equity firms or advisors, are becoming more active in acquiring European assets, an investment banker said on Tuesday.
“There are quite a lot of these chemical companies that are listed on the Chinese stock exchange with a strong drive to expand or diversify, and buy European and US assets to achieve a global market leading position, and thereby sustain the further development of the stock price,” said Bernd Schneider, managing director and global head of chemicals at Germany-based investment bank Alantra.
“If a deal makes sense from a strategic perspective, the Chinese government will approve an outbound deal, despite the official constraints on capital outflows,” he added.
Thus, the acquisition targets will typically have a significant technology and formulation component that can be leveraged in the China market, he noted.
“Many of the buyers are new chemical companies, including smaller conglomerates, that even many industry practitioners have never heard of – they may have $100m-$300m in annual revenues and are listed on an exchange. They often have significant firepower, sometimes with the ability to buy companies with revenues larger than their own,” said Schneider.
“The typical logic of whether company A can buy company B based on size and operational synergies doesn’t work with many Chinese buyers – you have to look behind the Chinese curtain,” he added.
These companies can secure the funds to close a deal either by raising more equity capital, deploying capital from government-owned investment vehicles, or by partnering with private equity firms that bring deal experience to the table and are specialised in acquiring Western assets to leverage their potential in China markets.
One example of such a private equity firm is AGIC (Asia-Germany Industrial Promotion) Capital, which describes itself as “the leading Asian-European private equity firm focused on industrial technology investments in Europe”.
AGIC is led by Henry Cai, formerly executive chairman of Investment Banking Asia Pacific at Deutsche Bank, before starting up AGIC in 2015. During his investment banking career of over 20 years, including at UBS and BNP Paribas, he helped bring around 200 Chinese state-owned and private companies to the public marketplace, according to AGIC.
Among the major investors in AGIC is China’s sovereign wealth fund China Investment Corp. AGIC initially raised $1bn for its first fund and is now seeking another $2bn-$3bn for its second, to be completed later in 2017.
AGIC seeks mid-sized technology oriented acquisitions in Europe, including in advanced materials and technologies. Among the subsectors in this category are high performance plastics, polymers and alloys, along with biodegradable materials, nanotechnology and carbon fibre components.
While it has yet to buy a chemical or plastics producer, in January 2016 AGIC partnered with ChemChina and GuoXin to buy Germany-based plastics and rubber processing machinery company KraussMaffei Group for €925m as its first investment.
Another such specialised private equity firm is Mandarin Capital Partners, which focuses on buying mid-size European businesses with “significant market potential in China”.
Mandarin acquired and sold a majority stake in Italy-based performance additives and specialty chemicals producer ItalMatch (acquired in 2010, sold in 2014) and in 2014 bought a majority stake in Italy’s Industrie Chimiche Forestali, a producer of adhesives and fabrics for a wide range of consumer applications.
Often these specialised private equity firms act as intermediaries for Chinese buyers, said the banker.
“Often you don’t see the chairman of a Chinese company engaging directly in the acquisition process. Instead it is a private equity vehicle or in some cases an advisor with knowledge on how to do these deals,” said Schneider.
“The private equity fund takes a majority stake and then sells it back to the trade buyer, either immediately or in a few years. But it usually has the ultimate buyer in mind on day one,” he added.
For a number of mid-size Chinese chemical companies, acquiring Western businesses, in particular with technological and formulation expertise, is a natural next step in their development, the banker noted.
By Joseph Chang
Source: ICIS News
Corteva (Indianapolis, Indiana) says it has signed a definitive agreement to acquire Stoller Group (Houston, Texas), a producer of biostimulants and plant nutrition products, for $1.2 billion. Stoller is one of the largest independent biologicals companies globally, with operations in more than 60 countries and more than $400 million in annual sales.
OMV has announced its new corporate structure today, designed to fully enable the delivery of Strategy 2030. The new organization will be built on five distinct areas. In addition to the CEO and CFO areas, three business segments will be established: Chemicals & Materials, Fuels & Feedstock, and Energy.
The European petchem sector is readying for some tough quarters. It’s a different picture in the US. So is this the best time ever to find a new role in the chemical industry? If you are in Europe, you would expect me to say probably not. But actually, it depends. So let me give you four answers to this question.